Ficolin-3 has been associated with metabolic diseases including gestational, prediabetes, and type 2 diabetes (139, 140), and identified as biomarkers in axial spondyloarthritis (141) and as a prognostic biomarker for esophageal cancer (142). Here, FCN3 is linked to metabolic disease.